- Status:
- Red
- Decision Date:
- December 2022
Comments
RED: Ziconotide (intrathecal delivery)
for chronic cancer pain. Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again
